Class II · Moderate risk Ongoing
Buprenorphine HCl
Reason Crystallization; identified as Buprenorphine free base
Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg
Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.
Why it was recalled
Failed Impurities/Degradation Specifications
What was recalled
Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30 count HDPE bottles, Rx Only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0093-5721-56
- Recalling firm
- Teva Pharmaceuticals USA
- NDC code
- 0093-5721-56
- Origin
- PA, United States
- Initiated by
- Voluntary: Firm initiated
- FDA recall number
- D-0517-2017
What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.
Other Buprenorphine recalls
See all
Class II · Moderate risk Ongoing
Buprenorphine Hydrochloride
Reason Crystallization; identified as Buprenorphine free base
Class II · Moderate risk Ongoing
Buprenorphine Hydrochloride Injection
Reason Lack of Assurance of Sterility-The potential for incomplete crimp seals.
Class II · Moderate risk Terminated
Buprenorphine Sublingual Tablets
Reason CGMP Deviations
Class III · Low risk Terminated
Buprenorphine Transdermal System
Reason Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint.
Get an alert if your medication is recalled
Tell us which medications you take. If the FDA recalls one, we email you - in plain English, with what to do. Free.